Basiliximab and Rabbit Anti-thymocyte Globulin for Prophylaxis of Acute Rejection After Heart Transplantation: A Non-inferiority Trial

Journal of Heart and Lung Transplantation

Volumn 26, Issue 3, 2007, Pages 258-263

  Carrier, Michel ^a   Leblanc, Marie Hélène ^b   Perrault, Louis P ^a   White, Michel ^a   Doyle, Daniel ^b   Beaudoin, Danielle ^a   Guertin, Marie Claude ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ALPHA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RABBIT ANTITHYMOCYTE GLOBULIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AGRANULOCYTOSIS; ANAPHYLACTIC SHOCK; ARTHRALGIA; ARTICLE; CANADA; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG EFFICACY; HEART TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VIRUS LOAD;

ACUTE DISEASE; ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RABBITS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33847405816     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.01.006     Document Type: Article

References (17)

1. Copeland J.G., Icenogle T.B., William R.J., et al. Rabbit antithymocyte globulin. A 10-year experience in cardiac transplantation. J Thorac Cardiovasc Surg 99 (1990) 852-860
2. Carrier M., Pelletier G.B., Cartier R., Leclerc Y., Robitaille D., and Pelletier L.C. Induction of immunosuppression with rabbit antithymocyte globulin: Five-year experience in cardiac transplantation. Can J Cardiol 9 (1993) 171-176
3. Vincenti F., Kirkman R., Light S., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338 (1998) 161-165
4. Beniaminovitz A., Itescu S., Lietz K., et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342 (2000) 613-619
5. Kahan B.D., Rajagopalan P.R., Hall M., and United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 67 (1999) 276-284
6. Nashan B., Moore R., Amlot P., Schmidt A.G., Abeywickrama K., Soulillou J.P., and CHIB 201 International Study Group. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350 (1997) 1193-1198
7. Mehra M.R., Zucker M.J., Wagoner L., et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 24 (2005) 1297-1304
8. Beniaminovitz A., Itescu S., Lietz K., Donovan M., Buke E.M., Groff B.D., et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with monoclonal antibody. N Engl J Med 342 (2000) 647-648
9. Hershberger R.E., Starling R.C., Eisen H.J., et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352 (2005) 2705-2713
10. Piaggio G., Elbourne D.R., Altman D.G., Pocock S.J., Evans S.J.W., and Consort Group. Reporting of noninferiority and equivalence randomized trials. JAMA 295 (2006) 1152-1160
11. Preiksaitis J.K., Brennan D.C., Fishman J., and Allen U. Canadian society of transplantation workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5 (2005) 218-227
12. Humar A., Paya C., Pescovitz M.D., et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 4 (2004) 644-649
13. Carrier M., White M., Perrault L.P., et al. A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant 18 (1999) 1218-1223
14. Blackwelder W.C. Proving the null hypothesis in clinical trials. Controlled Clin Trials 3 (1982) 345-353
15. Com-Nougue C., Rodary C., and Patte C. How to establish equivalence when data are censored: A randomized trial of treatments for B non-Hodgkin. Stat Med 12 (1993) 1353-1364
16. Flaman F., Zieroth S., Rao V., Ross H., and Delgado D.H. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant 25 (2006) 1358-1362
17. Brennan D.C., Daller J.A., Lake K.D., Cibrik D., Del Castillo D., and Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355 (2006) 1967-1977